Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
132 patient zenuzolac late treatment RCT: 200% higher mortality (p=0.34), 1% worse recovery (p=0.99), and 1% shorter hospitalization (p=0.87).
RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment.
Apr 2025, NCT04590547, https://clinicaltrials.gov/study/NCT04590547, https://c19p.org/kane